Auxilium Pharmaceuticals to Announce First Quarter 2005 Results
and Conduct Conference Call on Thursday, May 5, 2005
NORRISTOWN, Pa., April 29 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals,
Inc. (NASDAQ:AUXL), a fully integrated specialty pharmaceutical company with a
focus on urology and sexual health, will release results for the first quarter
of 2005 on Thursday, May 5, 2005. The Company will also conduct a conference
call that day at 10:00 a.m. ET to discuss results and highlights of the first
quarter, including its recent co-promotion agreement with Oscient
Pharmaceuticals for Testim(R) 1% testosterone gel.
Ms. Gerri Henwood, Auxilium's Chief Executive Officer, will host the conference
call.
Conference call details:
Date: Thursday, May 5, 2005
Time: 10:00 a.m. ET
Dial-in (U.S.): 877-407-8031
Dial-in (International): 201-689-8031
Web cast: http://www.auxilium.com/ To access an audio replay of the call:
Access number (U.S.): 877-660-6853
Access number (International): 201-612-7415
Account code: #286
Conference ID#: 150074 As previously reported, Ms. Gerri Henwood will participate in Oscient
Pharmaceuticals' (NASDAQ:OSCI) conference call to discuss Oscient's first
quarter financial results on Monday, May 2, 2005 prior to the opening of the
U.S. financial markets.
About Auxilium Auxilium Pharmaceuticals, Inc., founded in 1999, is a fully integrated
specialty pharmaceutical company with a focus on urology and sexual health. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of
hypogonadism through its 100 person sales and marketing team and through its
co-promotion partner, Oscient Pharmaceuticals Corp. The company is developing
additional Testim line extensions in addition to a product in Phase II for
treatment of Peyronie's Disease as well as other products for urologic and
sexual health. For additional information, visit http://www.auxilium.com/.
Safe Harbor Statement In addition to historical facts or statements of current condition, this press
release contains forward-looking statements within the meaning of the "Safe
Harbor" provisions of The Private Securities Litigation Reform Act of 1995,
including statements regarding development of Testim line extensions and
product candidates for the treatment of Peyronie's Disease, as well as other
products for urologic and sexual health. All statements other than statements
of historical facts contained in this press release, including statements
regarding the business strategy and plans and objectives of management for
future operations, are forward-looking statements. The words "believe," "may,"
"could," "will," "estimate," "continue," "anticipate," "intend," "should,"
"plan," "expect," and similar expressions, as they relate to the Company, are
intended to identify forward-looking statements. Forward-looking statements
provide the Company's current expectations or forecasts of future events. The
Company's performance and financial results could differ materially from those
reflected in these forward-looking statements due to general financial,
economic, regulatory and political conditions affecting the biotechnology and
pharmaceutical industries. For a discussion of the risks and uncertainties,
which could cause actual results to differ from those contained in the
forward-looking statements, see "Factors That May Affect Our Future Results" in
the Company's Form 10-K for the period ended December 31, 2004, which is on
file with the Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove to be
incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. The Company undertakes no obligation to update
publicly any forward-looking statement. DATASOURCE: Auxilium Pharmaceuticals, Inc.
CONTACT: Neil Lansing, Chief Financial Officer, Auxilium Pharmaceuticals, Inc., +1-610-239-8850, ; or Felicia Vonella, +1-212-843-0210, , of Lazar Partners, Ltd.
for Auxilium Pharmaceuticals, Inc.
Web site: http://www.auxilium.com/
|